Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study

BACKGROUND: In Non-small cell lung cancer (NSCLC), an overactive epidermal growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two tyrosine kinase inhibitors (TKIs) of EGFR, gefinitib and erlotinib, have been used with variable benefit. METHODS: We have analyzed outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Ivette F, Battelli, Chiara, Auclair, Paul L, Carrier, Kathleen, Hayes, Daniel M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758901/
https://www.ncbi.nlm.nih.gov/pubmed/19765296
http://dx.doi.org/10.1186/1471-2407-9-333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758901/
https://www.ncbi.nlm.nih.gov/pubmed/19765296
http://dx.doi.org/10.1186/1471-2407-9-333

Ejemplares similares